Insider Selling: Jazz Pharmaceuticals plc (NASDAQ:JAZZ) CEO Sells $185,625.00 in Stock

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) CEO Bruce C. Cozadd sold 1,500 shares of Jazz Pharmaceuticals stock in a transaction dated Tuesday, April 1st. The shares were sold at an average price of $123.75, for a total transaction of $185,625.00. Following the completion of the transaction, the chief executive officer now directly owns 440,307 shares of the company’s stock, valued at $54,487,991.25. This trade represents a 0.34 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Jazz Pharmaceuticals Price Performance

Shares of NASDAQ:JAZZ opened at $110.04 on Friday. The stock has a market cap of $6.68 billion, a price-to-earnings ratio of 15.50, a PEG ratio of 1.04 and a beta of 0.42. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. Jazz Pharmaceuticals plc has a 12 month low of $99.06 and a 12 month high of $148.06. The stock’s 50 day moving average price is $132.27 and its 200 day moving average price is $122.99.

Wall Street Analyst Weigh In

A number of brokerages have commented on JAZZ. Cantor Fitzgerald downgraded Jazz Pharmaceuticals from an “overweight” rating to a “neutral” rating and lifted their target price for the company from $140.00 to $150.00 in a research note on Wednesday, February 26th. UBS Group upgraded Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $145.00 to $179.00 in a research note on Friday, March 7th. Truist Financial raised their target price on Jazz Pharmaceuticals from $220.00 to $230.00 and gave the company a “buy” rating in a research note on Thursday, March 6th. Wells Fargo & Company raised shares of Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and boosted their price target for the company from $130.00 to $170.00 in a report on Thursday, February 13th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $210.00 price objective on shares of Jazz Pharmaceuticals in a report on Wednesday, March 5th. One equities research analyst has rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Jazz Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $187.71.

Institutional Trading of Jazz Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of JAZZ. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in Jazz Pharmaceuticals by 135.3% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 174,078 shares of the specialty pharmaceutical company’s stock worth $19,394,000 after acquiring an additional 100,112 shares during the period. Centre Asset Management LLC bought a new position in shares of Jazz Pharmaceuticals during the 4th quarter valued at about $9,335,000. Moloney Securities Asset Management LLC acquired a new position in shares of Jazz Pharmaceuticals in the 4th quarter worth approximately $464,000. Franklin Resources Inc. raised its holdings in shares of Jazz Pharmaceuticals by 4.6% in the 3rd quarter. Franklin Resources Inc. now owns 1,118,688 shares of the specialty pharmaceutical company’s stock worth $124,208,000 after purchasing an additional 48,708 shares in the last quarter. Finally, Hennion & Walsh Asset Management Inc. lifted its stake in Jazz Pharmaceuticals by 13.7% during the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 35,894 shares of the specialty pharmaceutical company’s stock valued at $4,420,000 after purchasing an additional 4,332 shares during the last quarter. Institutional investors own 89.14% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.